ArticleIsrael journal of chemistry2026
R17 Drives Heparan Sulfate Clearance via Endolysosomal Trafficking.
Article in Israel journal of chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Heparan sulfate (HS) proteoglycans are information-rich macromolecules that can orchestrate extracellular signaling and cargo uptake across diverse cellular contexts. Ligands that can engage cell surface HS possess significant potential as probes to investigate or manipulate cell-matrix interactions. Here, we show that R17, an HS-binding protein from the rodent herpesvirus Peru, actively remodels the glycocalyx of pancreatic cancer cells. Recombinant R17 bound heparin in vitro and associated with the surface of pancreatic cancer cells to promote the dose-dependent clearance of HS via trafficking to lysosomes. R17 also reduced wound closure without detectable cytotoxicity, indicative of the ability of R17 to suppress cellular migration. Notably, HS depletion persisted upon cation-independent mannose-6-phosphate receptor knockdown, suggesting that clearance is independent of this mechanism. These findings identify R17 as an exogenous HS-binding protein that can drive HS clearance via endolysosomal trafficking and suggest an alternative approach to modulate HS-dependent functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.